ARCALYST Performance and Market - Kiniksa expects ARCALYST net product revenue of $220 million to $230 million in 2023, representing approximately 84% growth at the midpoint[13,51] - ARCALYST has achieved only about 5% penetration of the target recurrent pericarditis population as of the end of 2022[13] - Approximately 14,000 recurrent pericarditis patients in the U S suffer from persistent underlying disease[28] - The addressable U S opportunity for ARCALYST is estimated to be approximately 14,000 patients, with about 7,000 new patients entering the target pool annually[33,36] - In Q2 2023, ARCALYST product revenue reached $54.5 million, representing approximately 100% year-over-year growth[38] Financial Position and Licensing Agreements - Kiniksa's cash position was $185 million as of Q2 2023[13,21] - The company's cash runway extends into at least 2027, supported by a profitable ARCALYST collaboration and revenue from out-licensing agreements[13,21] - Kiniksa received a $22 million upfront payment from Huadong Medicine and is eligible for up to approximately $640 million in milestones and royalties[24] - Kiniksa has received $100 million in upfront and near-term payments from the Genentech transaction, and is eligible for up to approximately $600 million in milestones[24] KPL-404 Development - KPL-404, a potentially best-in-class asset, is currently in a Phase 2 study for rheumatoid arthritis[14,18] - The Phase 2 trial for KPL-404 in rheumatoid arthritis is a multiple-ascending-dose study evaluating PK and safety, transitioning into a parallel dose efficacy portion[72]